Clearbridge Investments LLC Purchases Shares of 407,794 Dyne Therapeutics, Inc. $DYN

Clearbridge Investments LLC purchased a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 407,794 shares of the company’s stock, valued at approximately $7,976,000.

Other institutional investors also recently modified their holdings of the company. Creative Planning raised its stake in Dyne Therapeutics by 6.8% during the 3rd quarter. Creative Planning now owns 15,527 shares of the company’s stock valued at $196,000 after purchasing an additional 986 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Dyne Therapeutics by 26.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock valued at $136,000 after purchasing an additional 1,440 shares during the period. Caxton Associates LLP raised its stake in Dyne Therapeutics by 10.9% during the 2nd quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock valued at $158,000 after purchasing an additional 1,627 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in Dyne Therapeutics by 9.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 24,937 shares of the company’s stock valued at $315,000 after purchasing an additional 2,108 shares during the period. Finally, Strs Ohio acquired a new stake in Dyne Therapeutics during the 4th quarter valued at $51,000. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Trading Down 1.4%

Shares of NASDAQ:DYN opened at $17.67 on Thursday. The stock has a market capitalization of $2.92 billion, a PE ratio of -5.49 and a beta of 1.09. Dyne Therapeutics, Inc. has a 1 year low of $8.06 and a 1 year high of $25.00. The firm has a fifty day moving average price of $18.27 and a 200 day moving average price of $18.20. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter in the prior year, the firm earned ($1.05) earnings per share. Analysts expect that Dyne Therapeutics, Inc. will post -3 EPS for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, Director Brian S. Posner acquired 2,000 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The stock was purchased at an average cost of $16.94 per share, for a total transaction of $33,880.00. Following the completion of the acquisition, the director owned 24,500 shares of the company’s stock, valued at approximately $415,030. This trade represents a 8.89% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jason P. Rhodes sold 83,219 shares of the company’s stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $18.18, for a total transaction of $1,512,921.42. Following the completion of the sale, the director owned 7,962 shares of the company’s stock, valued at $144,749.16. This represents a 91.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders purchased 9,000 shares of company stock valued at $156,800 and sold 1,559,462 shares valued at $29,814,746. Company insiders own 9.46% of the company’s stock.

Analyst Upgrades and Downgrades

DYN has been the topic of several recent analyst reports. Sanford C. Bernstein boosted their target price on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Wall Street Zen raised shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Evercore set a $33.00 target price on shares of Dyne Therapeutics in a research note on Friday, May 15th. Finally, Morgan Stanley cut their target price on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research note on Monday, March 2nd. Three research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $35.00.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.